Material-detailed description

Microarray study
Fresh-frozen (FF) material from 52 tumours (27 FTC, 25 FTA) was used for the microarray study.
Surgical procedures on patients were performed in Polish and German centres at the MSC Memorial
Cancer Center and Institute of Oncology in Gliwice (28 subjects), University of Leipzig, University of Halle, and Mainz University Hospital (24 subjects). The patient characteristics given below refer to the Gliwice group only. There were 26 women and 2 men in the Gliwice group, 23 diagnosed with FTA and 5 with FTC (among them 3 patients with widely invasive FTC). The mean age at diagnosis was 47.2 years, with a median of 45.5 years (range: 14-72 years). Eight subjects (among them 3 diagnosed with FTC) underwent primary total thyroidectomy, 15 underwent lobectomy, and the remaining 5 underwent thyroid lobectomy with partial or subtotal resection of a contralateral lobe. The mean and median tumour diameter were 27 mm and 23 mm, respectively (range: 10-55 mm). However, the tumour diameter was unknown in 3 patients. Two patients with FTA were also diagnosed with low risk papillary thyroid cancer. Complementary radioiodine (RAI) ablation was carried out in both patients who achieved complete remission. For the FTC patients, distant metastases (bones and lungs)
were present at diagnosis in 2 patients, whereas one subject had local recurrence and distant metastases (mediastinum and lungs) 8 years after the initial diagnosis. Two were RAI-refractory, while RAI treatment with a cumulative activity of 500 mCi resulted in FTC stabilisation for another patient. One remaining FTC patient achieved complete remission after surgery and RAI ablation. The mean time to follow-up in the whole group was 3.7 years (range: 0-12 years).
Validation study
Forty patients were diagnosed with follicular thyroid adenoma (FTA subgroup) and 31 with follicular thyroid carcinoma (FTC subgroup).
The FTA subgroup included 35 women and 5 men, with a mean age at diagnosis of 46.3 years and a median of 45 years (range: 19-79 years). Twenty-seven subjects underwent thyroid lobectomy, and 12 underwent total thyroidectomy. No information regarding the extent of surgery was identifiable for one patient. The median and mean tumour diameter were 27.5 mm and 30.2 mm, respectively (range: 10-80 mm). Twelve patients demonstrated no tumour recurrence, and one patient was diagnosed with nodular goitre in a contralateral thyroid lobe. For 27 remaining subjects there were no data related to the further course of the disease. The mean time to follow-up was 2 years (range 0-9 years).
The FTC subgroup included 21 women and 10 men, with a mean age at FTC diagnosis of 57 years, and a median of 59 years (range 24-83 years). Four patients were diagnosed with widely invasive FTC. The mean tumour diameter was 38.3 mm, with a median of 33.5 mm (range 15-110 mm).
However, in 13 cases, no information regarding the tumour was provided. T1, T2, T3, and T4 features were diagnosed in 4, 11, 10, and 1 patient, respectively. Five remaining subjects were staged as Tx.
Multifocal tumour growth was observed in 11 subjects. Four patients demonstrated lymph node metastases (N1) and 5 distant metastases at FTC onset. Twenty-four patients underwent total thyroidectomy; among them primary total thyroid resection was carried out in 10 subjects and two stage procedure in 14 subjects. Six patients underwent surgery primarily due to nodular goitre a few years earlier (all of them finally had total thyroidectomy). Palliative surgery was performed in one remaining patient. All but one were treated with RAI. Seventeen subjects received therapeutic RAI activity only once, whereas 7 subjects required 2 courses of RAI ablation. Six patients with disseminated disease were treated with RAI 3 times or more. Seven patients were RAI refractory. Two subjects additionally underwent external beam radiation (one patient as a palliative procedure). One patient was given sorafenib. Finally, complete remission was observed in 18 patients, asymptomatic hyperthyroglobulinaemia in 3 subjects, partial regression in 1 subject, stable disease in 2 patients, and progressive disease in 6 patients. One patient died due to FTC. The mean time to follow-up was 7.4 years (range: 0-13 years). Figure S1 . Boxplots from the microarray data set (52 samples, both primary and secondary microarray datasets) with oncocytic and PDTC samples color-coded. Red: PDTC; blue: oncocytic. The solid circles represent samples with RAS mutation. The number of samples describes the samples in the high-throughput gene expression experiments. The number of genes means the number of distinct genes for which it was possible to assign an Entrez ID. Table S5 . Primer design for RAS mutation profiling. Three first primers marked "_FF" were used for freshly frozen materials and all regions containing 3 mutation sites were amplified. Other primers were used for the FFPE materials. 
